the aid library

LIST OPTIONS

Filter

6319

Chinese development assistance and household welfare in sub-Saharan Africa

Bruno Martorano, Laura Metzger, Marco Sanfilippo European University Institute (2019) C1

We combine data on Chinese development projects with data from Demographic and Health Surveys to study the impact of Chinese aid on household welfare in sub-Saharan Africa. We use a novel methodology to test the effect of Chinese aid on three important development outcomes: education, health, and nu... more

External Link

Countdown to 2015: an analysis of donor funding for prenatal and neonatal health, 2003–2013

Pitt, C.; C. Grollman; M. Martínez-Álvarez et al. BMJ Global Health (2017) C1

Background: In 2015, 5.3 million babies died in the third trimester of pregnancy and first month following birth. Progress in reducing neonatal mortality and stillbirth rates has lagged behind the substantial progress in reducing postneonatal and maternal mortality rates. The benefits to prenatal an... more

Download (94)

View PDF (93)

Fight for what counts. Investment Case

The Global Fund (2022) CC

Over the 20 years that followed, this unique partnership has invested more than US$53 billion, saving 44 million lives and reducing the combined death rate from the three diseases by more than half in the countries in which the Global Fund invests.

Download (143)

View PDF (146)

Kenya: Multi-Sectorial Cholera Elimination Plan

Global Task Force On Cholera Control (GTFCC) (2022) CC

Cholera remains an issue of major public health importance in Kenya. Kenya has in recent years experienced outbreaks affecting different parts of the country

Download (157)

View PDF (175)

Clinical management of COVID-19: Living guideline, 18 August 2023

World Health Organisation (WHO) (2023) C_WHO

The WHO COVID-19 Clinical management: living guidance contains the most up-to-date recommendations for the clinical management of people with COVID-19. Providing guidance that is comprehensive and holistic for the optimal care of COVID-19 patients throughout their entire illness is important.

Download (166)

View PDF (146)

Public health resource pack for countries experiencing outbreaks of influenza in animals: revised guidance

World Health Organisation (WHO) (2023) C_WHO

This resource pack was developed for the country offices of the World Health Organization and national Public Health institutions, as an overview of the key information needed for advising their Member States in response to questions raised on human health due to influenza outbreaks or detections in... more

Download (174)

View PDF (164)

Ethiopia: Cholera Outbreak- Flash Update #8

United Nations Office for the Coordination of Humanitarian Affairs (OCHA) Reliefweb (2023) C_WHO

20 June 2023

Download (190)

View PDF (188)

Global Strategic preparedness, readiness and response plan for Cholera
recommended

World Health Organisation (WHO) (2023) CC

Cholera is a major health risk in many parts of the world, affecting millions of people every year. Since mid-2021, the world has been facing an acute upsurge of the 7th cholera pandemic, which is characterized by the number, size and concurrence of multiple outbreaks, the spread to areas that had b... more

External Link

Macroeconomics and health : investing in health for economic development / report of the Commission on Macroeconomics and Health

World Health Organization WHO (2002) C_WHO

The Commission on Macroeconomics and Health (CMH) was established by World Health Organization Director-General Gro Harlem Brundtland in January 2000 to assess the place of health in global economic development. Although health is widely understood to be both a central goal and an important outcome ... more

External Link

Financing Global Health 2014: Shifts in Funding as the MDG Era Closes

Institute for Health Metrics and Evaluation (2015) CC

Financing Global Health 2014 is the sixth edition of this annually produced report on global health financing. As in previous years, this report captures trends in development assistance for health (DAH) and government health expenditure (GHE). Health financing is one of IHME’s core research areas... more

Download (335)

View PDF (139)

Financing Global Health 2015: Development assistance steady on the path to new Global Goals

Institute for Health Metrics and Evaluation (2016) CC

Financing Global Health 2015 is the seventh edition of IHME’s annual series on global health financing. This report captures trends in development assistance for health (DAH) and government health expenditure as source (GHE-S) in low- and middle-income countries. Annually updated GHE-S and DAH est... more

Download (110)

View PDF (138)

Tracking aid flows for development assistance for health

Vassall A.; Shotton J.; Klein O. et al Global Health Action (2014) CC

he global architecture for providing development assistance for health (DAH) has become increasing complex in the last decade, with many new funding agencies entering the health sector. This study presents a detailed picture of European Union (EU) and EU member state originating DAH between 2006 ... more

Download (126)

View PDF (136)

Tracking aid for global health goals: a systematic comparison of four approaches applied to reproductive, maternal, newborn, and child health

Pitt C.; Grollman C.; Martinez-Alvarez M. et al The Lancet (2018) CC

Four initiatives have estimated the value of aid for reproductive, maternal, newborn, and child health (RMNCH): Countdown to 2015, the Institute for Health Metrics and Evaluation (IHME), the Muskoka Initiative, and the Organisation for Economic Co-operation and Development (OECD) policy marker. We... more

Download (242)

View PDF (222)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 9 October 2023

World Health Organization WHO (2023) CC

The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline... more

Download (176)

View PDF (321)

WASH FIT: A practical guide for improving quality of care through water, sanitation and hygiene in health care facilities (Second edition)

UN Children's Fund UNICEF; World Health Organization WHO (2023) C_WHO

Fully functioning water, sanitation, hygiene (WASH) and health care waste management services are a critical aspect of infection prevention and control (IPC) practices, and ensuring patient safety and quality of care. Such services are also essential for creating an environment that supports the dig... more

External Link

Climate Risk Sourcebook

Deutsche Gesellschaft für Internationale Zusammenarbeit GIZ; Eurac Research; United Nations University (2023) CC

Climate change is one of the most urgent challenges for people and ecosystems worldwide. The recently published sixth Assessment Report (AR6) of the Intergovernmental Panel on Climate Change (IPCC) stresses the occurrence of widespread adverse impacts of climate change. Increased frequency and inten... more

Download (284)

View PDF (380)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Global Strategic preparedness, readiness and response plan for Cholera recommended

Global Strategic preparedness, readiness and response plan for Cholera
recommended